FDA Approves Groundbreaking Twice-Yearly HIV Prevention Shot

A major breakthrough in the fight against HIV has just been announced. The Food and Drug Administration (FDA) has approved a new injectable medication, called Yes2Go, for use as a preventive treatment against HIV.

Unlike daily oral medications currently on the market, Yes2Go is administered just twice a year, making it a significant advancement in long-term HIV prevention. Clinical trials have shown the drug to be extremely effective, nearly eliminating the risk of HIV transmission for those who take it consistently.

Experts are hailing it as a game changer—especially for communities where daily adherence to pills can be a challenge. The medication could dramatically improve outcomes and accelerate progress in curbing the spread of HIV across the United States.

However, there's a significant barrier: the cost. Each injection carries a price tag of more than $14,000, which raises serious questions about accessibility and insurance coverage.

Health officials say efforts are already underway to expand financial assistance programs and explore options to make the drug more widely available.

Explore: NBCPalmSprings.com, where we are connecting the Valley.